BriaCell Therapeutics (BCTX, Financial) has reached a significant milestone in its ongoing Phase 3 clinical study by consenting over 100 patients and enrolling more than 75. The study is focused on evaluating the efficacy of BriaCell's lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, as compared to options chosen by physicians, for patients with advanced metastatic breast cancer.
The company aims to complete patient enrollment by late 2025 or early 2026. Should everything proceed as planned, BriaCell anticipates reporting top-line data in the first half of 2026. This progress is crucial for BriaCell's mission to transform cancer care for individuals battling metastatic breast cancer.
The President and CEO of BriaCell, Dr. William V. Williams, expressed optimism regarding the expanding patient enrollment and emphasized the company's commitment to bringing this innovative immunotherapy to market. The ultimate goal is to offer a novel therapeutic approach that could significantly impact the treatment landscape for metastatic breast cancer patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for BriaCell Therapeutics Corp (BCTX, Financial) is $225.00 with a high estimate of $225.00 and a low estimate of $225.00. The average target implies an upside of 5,269.93% from the current price of $4.19. More detailed estimate data can be found on the BriaCell Therapeutics Corp (BCTX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, BriaCell Therapeutics Corp's (BCTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
